Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 805 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer MOST POPULAR A Nurse’s Love For Oncology Patients May 20, 2021 No Benefit for Post-operative Radiotherapy in Non-small-cell Lung Cancer [ESMO2020 Press... September 20, 2020 Cancer in My Community: Overcoming Delays in Care for Children With... July 6, 2023 ΚΑΡΚΙΝΟΣ ΣΤΟ ΣΥΚΩΤΙ February 7, 2019 Load more HOT NEWS FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... EMA Recommends Additional Extensions of Indications for Pembrolizumab Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma
